Detalhe da pesquisa
1.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
2.
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
Am J Hematol
; 94(5): 554-562, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30767298
3.
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Br J Haematol
; 178(2): 286-291, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28397242
4.
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
Br J Haematol
; 186(1): 184-188, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30740654
5.
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
Open Forum Infect Dis
; 9(5): ofac104, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35493119
6.
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Clin Cancer Res
; 28(20): 4385-4391, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35939599
7.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
J Clin Oncol
; 39(34): 3853-3865, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618601
8.
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Hematology
; 25(1): 112-117, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32131714
9.
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Leuk Lymphoma
; 60(4): 1000-1005, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30277101
10.
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk
; 19(11): 715-722.e6, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31447270